ArticleKardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery2026
Medium-term results and the impact of structural valve deterioration of Trifecta versus Perceval bioprostheses: analysis from the Perfecta study.
Article in Kardiochirurgia i torakochirurgia polska = Polish journal of cardio-thoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Surgical aortic valve replacement remains the most effective treatment for severe aortic valve disease, thanks to the evolution and development of new-generation biological prostheses. Aim: The study aimed to compare the follow-up results of aortic valve replacement with implantation of the Perceval sutureless bioprosthesis and St. Jude Trifecta sutured bioprosthesis (the single-center Perfecta study), evaluating the following end-points: survival, event-free survival rates, and impact of structural valve deterioration (SVD) on freedom from reintervention. Material and methods: Between December 2014 and June 2023, 280 patients underwent aortic valve replacement with Trifecta ( Results: At 7 years for both bioprostheses, Trifecta vs.Perceval, survival (68 ±4.1% vs. 89 ±4.8%; Conclusions: Both bioprostheses appear to confer equally satisfactory late outcomes. Although the Trifecta prosthesis carries a higher risk of SVD, this risk does not seem to be significantly associated with worse clinical conditions or need for reoperation. The Perceval prosthesis can be considered a viable option in the context of the latest-generation bioprostheses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.